MeritValue

20/20 Biolabs, Inc.

AIDXdata completeness 75%2 fiscal years on file
The thesis, from the filings

20/20 Biolabs, Inc. earns about -369% on equity, but has diluted owners by 3% over 2 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below. Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2024FY 2025
Revenue$1.75M1$2.05M1
Net income−$5.55M2−$3.74M2
Operating cash flow−$2.6M3−$1.92M3
Capital expenditure——
Free cash flow (derived)——
Total debt——
Cash & equivalents$1.78M4$1.03M4
Diluted shares4.8M4.9M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom). A derived or summed figure cites every filing line it was built from.

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.04
your share of equity
Profit it earned you last year
−$7.58
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on −$0.04 of net worth that earned you −$7.58 last year.

iii. Is this a good business?
Moat signal · return on equity
-369% avg · 2y
FY24 -369%FY25 —

It earned an average -369% on equity over 2 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
+3% shares · 2y

Share count is up 3% over 2 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.6.0
DCF · Growth Exit 10Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
only 2 years of net income (need ≥3)
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Beyond this page

This page is free, and so is every other company on MeritValue.

In your AI assistant

Connect the MeritValue MCP server to Claude or another MCP client, ask about 20/20 Biolabs, Inc., and get these exact figures with their filing receipts — not an improvised DCF.

Get a free key →
Screen by model

Pull the companies with a published value under any model (up to 500 a request, filtered by data completeness) into your own sheet or agent. Screening is what Analyst adds, at $9/month.

See pricing →
On iPhone

Follow AIDX and keep your own price beside the value. The same engine, with the same receipts.

MeritValue on the App Store →
Sources — the receipts
  1. 10-K filed 2026-03-31 · periods ending 2024-12-31, 2025-12-31 · accession 0001213900-26-037667 (RevenueFromContractWithCustomerIncludingAssessedTax)
  2. 10-K filed 2026-03-31 · periods ending 2024-12-31, 2025-12-31 · accession 0001213900-26-037667 (NetIncomeLoss)
  3. 10-K filed 2026-03-31 · periods ending 2024-12-31, 2025-12-31 · accession 0001213900-26-037667 (NetCashProvidedByUsedInOperatingActivities)
  4. 10-K filed 2026-03-31 · periods ending 2024-12-31, 2025-12-31 · accession 0001213900-26-037667 (CashAndCashEquivalentsAtCarryingValue)